ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: PP03 • ACR Convergence 2020

    Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships

    Nancy Linn1, Catherine Bammert2, David Bammert3 and Michael Linn4, 1Relapsing Polychondritis Foundation, Palos Verdes Estates, CA, 2MD Anderson, Houston, TX, 3Relapsing Polychondritis Foundation, Houston, TX, 4Relapsing Polychondritis Foundation, New York, NY

    Background/Purpose: In 2011, I was diagnosed with relapsing polychondritis ("RP"), a debilitating and sometimes fatal rheumatic disease that is characterized by inflammation of cartilage and…
  • Abstract Number: 0366 • ACR Convergence 2020

    Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab

    Philip Mease1, Atul Deodhar2, Renato Calheiros3, Xiangyi Meng4, Todd Fox5 and Xenofon Baraliakos6, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Novartis Pharmaceuticals Corporation, Hoboken, NJ, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5Novartis Pharma AG, Aesch, Switzerland, 6Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton associated with pain, stiffness, and disability.1 Up to 66% of patients (pts)…
  • Abstract Number: 0700 • ACR Convergence 2020

    Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis

    Mandar Dave1, Abul Islam2, Akshat Parekh3, Jay Patel4, Arushi Chawla5 and Ashok Amin6, 1Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, 2Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh, 3Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, 4Northeast Ohio Medical University, Rootstown, OH, 5Gujarat Forensic Science University, Gujarat, India, 6Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, NY

    Background/Purpose: Human OA-affected cartilage does not show the cardinal signs of inflammation (redness and swelling with heat and pain—rubor et tumor cum calore et dolor) because…
  • Abstract Number: 0946 • ACR Convergence 2020

    ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin

    Sladjana Skopelja-Gardner1, Joyce Tai2, Xizhang Sun2 and Keith Elkon2, 1University of Washington, Seattle, WA, 2University of Washington, Seattle

    Background/Purpose: Systemic lupus erythematosus (SLE) patients have a prominent type I interferon (IFN-I) signature in both the lesional and non-lesional skin. We recently showed that…
  • Abstract Number: 1237 • ACR Convergence 2020

    Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials

    Anthony Sebba1, Jian Han2 and Shalini V. Mohan2, 1Arthritis Associates, Palm Harbor, Tampa, FL, 2Genentech, South San Francisco, CA

    Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
  • Abstract Number: 1577 • ACR Convergence 2020

    Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis

    Jeffrey Sarazin1, Ann Impens2, Nada Abdulaziz1, Stacey Anderson3, Leslie Fecher1, Christopher Lao1 and Elena Schiopu1, 1Michigan Medicine, Ann Arbor, MI, 2Midwestern University, Ann Arbor, IL, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
  • Abstract Number: PP04 • ACR Convergence 2020

    My Multidisciplinary Healthcare Team and Patient Advocacy Groups Saved My Life

    Tedi LaMere1, Michael Linn2 and David Bammert3, 1Relapsing Polychondritis Foundation, Kalispell, MT, 2Relapsing Polychondritis Foundation, New York, NY, 3Relapsing Polychondritis Foundation, Houston, TX

    Background/Purpose: I enjoyed being physically active my entire life – climbing mountains, hunting, and hiking. This drastically changed around 2012, when I noticed that I was…
  • Abstract Number: 0381 • ACR Convergence 2020

    Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis

    Ana-Maria Orbai1, Philip Mease2, Philip Helliwell3, Oliver FitzGerald4, Mohamed Bedaiwi5, Dona Fleishaker6, Rajiv Mundayat6 and Pamela Young7, 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 5Division of Rheumatology, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Dactylitis, a hallmark of psoriatic arthritis (PsA), is a uniformly diffuse and sometimes painful swelling of the fingers and/or toes.1 Up to 50% of…
  • Abstract Number: 0705 • ACR Convergence 2020

    lncRNA H19 and Micro RNA 675-3p Are Altered by Visfatin During Osteogenesis

    Dennis Küppers1, Lali Tsiklauri2, Marie-Lisa Hülser1, Klaus Frommer2, Stefan Rehart3, Caroline Ospelt4, Ulf Müller-Ladner5 and Elena Neumann6, 1Justus-Liebig-University Giessen, Campus Kerckhoff, Dept. of Rheumatology and Clinical Immunology, Giessen, Germany, 2Justus-Liebig-University Giessen, Campus Kerckhoff, Dept. of Rheumatology and Clinical Immunology, Bad Nauheim, Germany, 3Department of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital, Frankfurt, Frankfurt, Germany, 4University Hospital Zürich; University Hospital of Zurich; Center of Experimental Rheumatology, Department of Rheumatology, Zurich, Switzerland, 5Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, 6Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany

    Background/Purpose: Long non-coding (lnc-)RNAs are transcribed from DNA similar to mRNA. lncRNA are able to interact directly with DNA, RNA and proteins. Some lncRNAs contain…
  • Abstract Number: 0949 • ACR Convergence 2020

    SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation

    Daimon Simmons1, Hung Nguyen2, Emma Gomez-Rivas3, YunJu Jeong4, William Apruzzese5, Edy Kim6 and Michael Brenner7, 1Department of Pathology, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Brigham and Women's Hospital,, Boston, MA, 3Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 4Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boston, MA, 5., Boston, 6Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Monocytes orchestrate immune responses that protect against microbes but can also drive pathological inflammation and autoimmune disease. Monocytes are thought to be activated primarily…
  • Abstract Number: 1240 • ACR Convergence 2020

    An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis

    Muhammad Shipa1, Su-Ann Yeoh1, Dev Mukerjee2 and Michael Ehrenstein1, 1University College London, LONDON, United Kingdom, 2North Middlesex University hospital NHS Trust, London, United Kingdom

    Background/Purpose: Methotrexate (MTX) can result in an increase in mean corpuscular volume (MCV) of red blood cells. The range of MCV change varies between patients…
  • Abstract Number: 1637 • ACR Convergence 2020

    Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan

    Jun Shimizu1, Yoshihisa Yamano1, Kimito Kawahata2 and Noboru Suzuki1, 1St. Marianna University School of Medicine, Kawasaki, Japan, 2Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: We conducted a retrospective survey study in 2009 and collected clinical data of 239 patients with relapsing polychondritis (RP). Using the survey data, we…
  • Abstract Number: PP05 • ACR Convergence 2020

    Coping Through Advocacy – My Story Living with Relapsing Polychondritis

    Allegonda Imeson1, 1The Canadian Society for Relapsing Polychondritis, Stony Plain, AB, Canada

    Background/Purpose: Becoming a mother was the most pivotal moment of my life. From early on, I instilled the importance of a physical, healthy lifestyle for my two…
  • Abstract Number: 025 • 2020 Pediatric Rheumatology Symposium

    HLA Genetic Signatures Associated with Inflammatory Sub-type in Juvenile Localized Scleroderma

    Christina Schutt1, Emily Mirizio 2, Kaila Schollaert-Fitch 2 and Kathryn Torok 2, 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, 2Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh

    Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease of the skin and underlying tissue that is characterized by an earlier inflammatory infiltrate, followed by…
  • Abstract Number: L10 • 2019 ACR/ARP Annual Meeting

    Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis

    Roberta Gualtierotti1, Francesca Ingegnoli 2, Massimo Boscolo 3, Samantha Griffini 3, Elena Grovetti 4 and Massimo Cugno 5, 1Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Lombardia, Italy, 2UOC Reumatologia Clinica, ASST Pini-CTO, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy, 3Medicina Interna, Ospedale Maggiore Policlinico, IRCCS Fondazione Ca' Granda Milano, Italy, Milan, 4Medicina Interna, Ospedale Maggiore Policlinico, IRCCS Fondazione Ca' Granda Milano, Milan, 5Medicina Interna, Ospedale Maggiore Policlinico, IRCCS Fondazione Ca' Granda Milano, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease associated with a prothrombotic state. Tocilizumab, an interleukin-6 receptor inhibitor, is highly effective in controlling…
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 58
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology